Cargando…

CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a threatening hematological malignant disease in which new successful approaches in therapy are needed. Cyclin-dependent kinase 6 (CDK6), a regulatory enzyme of the cell cycle that plays an important role in leukemogenesis and the maintenance of leukemia stem cells (L...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei, Yi, Jin-Mou, Liu, Yi, Chen, Cong, Zhang, Kai-Xuan, Zhou, Cheng, Zhan, Hui-En, Zhao, Liang, Morales, Stephanie, Zhao, Xie-Lan, Zeng, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882723/
https://www.ncbi.nlm.nih.gov/pubmed/33597968
http://dx.doi.org/10.3389/fgene.2020.600227
_version_ 1783651105352187904
author Liu, Wei
Yi, Jin-Mou
Liu, Yi
Chen, Cong
Zhang, Kai-Xuan
Zhou, Cheng
Zhan, Hui-En
Zhao, Liang
Morales, Stephanie
Zhao, Xie-Lan
Zeng, Hui
author_facet Liu, Wei
Yi, Jin-Mou
Liu, Yi
Chen, Cong
Zhang, Kai-Xuan
Zhou, Cheng
Zhan, Hui-En
Zhao, Liang
Morales, Stephanie
Zhao, Xie-Lan
Zeng, Hui
author_sort Liu, Wei
collection PubMed
description Acute myeloid leukemia (AML) is a threatening hematological malignant disease in which new successful approaches in therapy are needed. Cyclin-dependent kinase 6 (CDK6), a regulatory enzyme of the cell cycle that plays an important role in leukemogenesis and the maintenance of leukemia stem cells (LSC), has the potential to predict the prognosis of AML. By analyzing public databases, we observed that the messenger RNA (mRNA) levels of CDK6 were significantly overexpressed in AML cell lines and non-acute promyelocytic leukemia (non-APL) AML patients when compared to healthy donors. Furthermore, CDK6 expression was significantly reduced in AML patients who achieved complete remission (CR) compared to that at the time of diagnosis in our validated cohort. The expression of CDK6 was tightly correlated with peripheral blood blasts, French–American–British (FAB) subtypes, CCAAT-enhancer-binding protein α (CEBPA) mutation, and chromosomal abnormalities of t(8;21). However, the clinical significance and effects of CDK6 expression on the prognosis of non-APL AML patients remain uncertain. We found that CDK6 expression was inversely correlated with overall survival (OS) among non-APL AML patients using the Kaplan–Meier analysis. CDK6 was also found to be positively associated with genes identified to contribute to the development of leukemia, including CCND2, DNMT3B, SOX4, and IKZF2, as well as being negatively associated with anticancer microRNAs, including miR-187, miR-9, miR-582, miR708, and miR-362. In summary, our study revealed that CDK6 might be a potential diagnostic and prognostic biomarker in non-APL AML patients.
format Online
Article
Text
id pubmed-7882723
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78827232021-02-16 CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia Liu, Wei Yi, Jin-Mou Liu, Yi Chen, Cong Zhang, Kai-Xuan Zhou, Cheng Zhan, Hui-En Zhao, Liang Morales, Stephanie Zhao, Xie-Lan Zeng, Hui Front Genet Genetics Acute myeloid leukemia (AML) is a threatening hematological malignant disease in which new successful approaches in therapy are needed. Cyclin-dependent kinase 6 (CDK6), a regulatory enzyme of the cell cycle that plays an important role in leukemogenesis and the maintenance of leukemia stem cells (LSC), has the potential to predict the prognosis of AML. By analyzing public databases, we observed that the messenger RNA (mRNA) levels of CDK6 were significantly overexpressed in AML cell lines and non-acute promyelocytic leukemia (non-APL) AML patients when compared to healthy donors. Furthermore, CDK6 expression was significantly reduced in AML patients who achieved complete remission (CR) compared to that at the time of diagnosis in our validated cohort. The expression of CDK6 was tightly correlated with peripheral blood blasts, French–American–British (FAB) subtypes, CCAAT-enhancer-binding protein α (CEBPA) mutation, and chromosomal abnormalities of t(8;21). However, the clinical significance and effects of CDK6 expression on the prognosis of non-APL AML patients remain uncertain. We found that CDK6 expression was inversely correlated with overall survival (OS) among non-APL AML patients using the Kaplan–Meier analysis. CDK6 was also found to be positively associated with genes identified to contribute to the development of leukemia, including CCND2, DNMT3B, SOX4, and IKZF2, as well as being negatively associated with anticancer microRNAs, including miR-187, miR-9, miR-582, miR708, and miR-362. In summary, our study revealed that CDK6 might be a potential diagnostic and prognostic biomarker in non-APL AML patients. Frontiers Media S.A. 2021-02-01 /pmc/articles/PMC7882723/ /pubmed/33597968 http://dx.doi.org/10.3389/fgene.2020.600227 Text en Copyright © 2021 Liu, Yi, Liu, Chen, Zhang, Zhou, Zhan, Zhao, Morales, Zhao and Zeng. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Genetics
Liu, Wei
Yi, Jin-Mou
Liu, Yi
Chen, Cong
Zhang, Kai-Xuan
Zhou, Cheng
Zhan, Hui-En
Zhao, Liang
Morales, Stephanie
Zhao, Xie-Lan
Zeng, Hui
CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
title CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
title_full CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
title_fullStr CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
title_full_unstemmed CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
title_short CDK6 Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia
title_sort cdk6 is a potential prognostic biomarker in acute myeloid leukemia
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882723/
https://www.ncbi.nlm.nih.gov/pubmed/33597968
http://dx.doi.org/10.3389/fgene.2020.600227
work_keys_str_mv AT liuwei cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia
AT yijinmou cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia
AT liuyi cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia
AT chencong cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia
AT zhangkaixuan cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia
AT zhoucheng cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia
AT zhanhuien cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia
AT zhaoliang cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia
AT moralesstephanie cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia
AT zhaoxielan cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia
AT zenghui cdk6isapotentialprognosticbiomarkerinacutemyeloidleukemia